LakeShore Biopharma Co., Ltd. (LSBCF)
↓ Download CSV- Sector Manufacturing
- Incorporated E9
- Fiscal year ends Mar 31
In fiscal 2025, LakeShore Biopharma Co., Ltd. reported revenue of 614.96M CNY, up 7.2% from the prior year. The company ran a net loss, with a net margin of -16.3% and a gross margin of 82.5%. It held 1.37B CNY in total assets against 867.91M CNY in total liabilities.
Key ratios (FY2025)
82.5%
Gross margin
-14.0%
Operating margin
-16.3%
Net margin
-20.0%
Return on equity
+7.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 614.96M CNY | 573.42M CNY | 687.20M CNY | 502.95M CNY | 257.02M CNY | — |
| Cost of Revenue | 107.77M CNY | 117.69M CNY | 153.36M CNY | 117.07M CNY | 59.66M CNY | — |
| Gross Profit | 507.19M CNY | 455.73M CNY | 533.84M CNY | 385.88M CNY | 197.36M CNY | — |
| Operating Income | -86.29M CNY | -445.83M CNY | -139.38M CNY | -118.96M CNY | -125.85M CNY | — |
| Net Income | -99.98M CNY | -433.46M CNY | -145.48M CNY | -106.00M CNY | -191.83M CNY | — |
| EPS (Diluted) | -5.22 CNY | -40.54 CNY | -23.55 CNY | -1.71 CNY | -3.10 CNY | — |
| Total Assets | 1.37B CNY | 1.51B CNY | 1.72B CNY | 1.44B CNY | — | — |
| Total Liabilities | 867.91M CNY | 927.82M CNY | 991.30M CNY | 770.50M CNY | — | — |
| Shareholders' Equity | 499.75M CNY | 585.21M CNY | 728.45M CNY | -698.97M CNY | -508.86M CNY | -847.32M CNY |
| Cash & Equivalents | — | — | 370.40M CNY | — | — | — |
| Operating Cash Flow | -120.98M CNY | -295.23M CNY | -182.47M CNY | -173.55M CNY | -246.61M CNY | — |
| Capital Expenditures | 12.71M CNY | 44.25M CNY | 52.76M CNY | 295.31M CNY | 104.88M CNY | — |
| Shares Outstanding | 19.16M | 10.69M | 6.18M | 61.83M | 61.83M | — |